Clinical trials: Conventional therapy
Congenital Adrenal Hyperplasia
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency.
- Trial name
- CAHtalyst (NCT04490915)
- Testing
- Crinecerfont
- Where
- 70 sites in United States, Austria and 16 more
- Volunteers
- 182 people
- Sponsor
- Neurocrine Biosciences
Unresectable Breast Cancer, Metastatic Breast Cancer
DESTINY Breast Respond HER2-(Ultra)Low Europe
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed…
- Conditions
- Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
- Trial name
- NCT05945732
- Testing
- Trastuzumab deruxtecan
- Where
- 216 sites in Austria, Belgium and 8 more
- Volunteers
- 2,295 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Carotid Artery Stenosis
Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)
Clinical Trial Summary Trial Title:** CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions Sponsor:** Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
- Trial name
- CREATE (NCT06936176)
- Testing
- Neurovascular Intravascular Shockwave Catheter
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Aortic Aneurysm
Radiation Free Study
This is a prospective, randomized, unblinded, multi-center study. Sites were selected from different geographies (EU and US) with different clinical practice to ensure the results are more generalizable.
- Trial name
- RadFree (NCT06549348)
- Testing
- Measure average procedure fluoroscopy time using LumiGuide and conventional fluoroscopy guidance
- Where
- 11 sites in United States, Belgium and 4 more
- Volunteers
- 182 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Congenital Adrenal Hyperplasia
A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])
This pre-screening study is designed to determine potential eligibility of adults with classic CAH due to 21-hydroxylase deficiency (21-OHD) for participation in the CAH-301 [NCT04783181] gene therapy trial with BBP-631.
- Trial name
- NCT05101902
- Testing
- Pre-Screening
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Adrenas Therapeutics Inc
Multiple Myeloma
the Safety and Efficacy of SENL103 Autologous T Cell Injection
To observe the safety and efficacy of SENL103 cells in the treatment of patients with recurrent or refractory plasma cell blood tumors.
- Trial name
- NCT06067581
- Testing
- SENL103
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Allergic Rhinitis
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
This was a multicenter, uncontrolled, open-label, special drug use study to investigate the safety and efficacy of Xolair by collecting data in its clinical setting in patients with severe to most severe seasonal allergic…
- Trial name
- NCT04648930
- Testing
- Xolair
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Contraception, Ovulation Inhibition
Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ
The purpose of this study is to determine whether the study drug is safe and effective.
- Conditions
- Contraception, Ovulation Inhibition, Contraceptives, Oral
- Trial name
- NCT00567164
- Testing
- EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
- Where
- 85 sites in United States
- Volunteers
- 1,887 people, healthy volunteers welcome
- Sponsor
- Bayer
Peripheral Vascular Disease
Impedance Sensor Evaluated in Peripheral Artery Disease for Tissue Detection
The objective of the study is to evaluate the feasibility of the CSGS sensor to differentiate tissues involved in Peripheral Artery Disease (PAD).
- Trial name
- SEPARATE (NCT06112054)
- Testing
- Clotild Smart Guidewire System (CSGS)
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Sensome
Tooth Hypersensitivity
NUPRO(r) Sensodyne Prophylaxis Paste With NovaMin(r)Sensitivity Relief Study
The study is intended to verify through clinical measurement that the NUPRO Sensodyne Prophylaxis Paste with Novamin provides immediate sensitivity relief as well as extended relief up to 28 days.
- Trial name
- NCT01610167
- Testing
- NUPRO Classic Prophy Paste, NUPRO Sensodyne Prophy Paste with Novamin with fluoride., NUPRO Sensodyne Prophy Paste with Novamin without fluoride.
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Dentsply International
Fabry Disease
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.
- Trial name
- NCT06270316
- Testing
- AMT-191
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- UniQure Biopharma B.V.
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Trastuzumab deruxtecan (T-DXD) as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior…
- Trial name
- NCT05993234
- Testing
- Trastuzumab deruxtecan
- Where
- 39 sites in Austria, Belgium and 2 more
- Volunteers
- 257 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Peripheral T-cell Lymphomas
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
The aim of this study is to evaluate anti-tumor safety and efficacy of endostar®（Human recombinant endostatin injection）combined with traditional GDP （gemcitabine+dexamethasone+cis-platinum）chemotherapy for newly diagnosed or…
- Trial name
- NCT02520219
- Testing
- GDP, Endostar
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib.
- Trial name
- CHONQUER (NCT06127407)
- Testing
- Ivosidenib 500mg
- Where
- 115 sites in United States, Australia and 15 more
- Volunteers
- 156 people
- Sponsor
- Servier Bio-Innovation LLC
Prostatic Neoplasms
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
The purpose of this study is to temporally evaluate the impact of abiraterone acetate (ZYTIGA) therapy on Patient Reported Outcomes (PROs) and on clinical outcomes in the chemotherapy-naive metastatic castrate-resistant prostate…
- Trial name
- COSMiC (NCT02364531)
- Testing
- Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry
- Where
- 41 sites in Canada
- Volunteers
- 194 people
- Sponsor
- Janssen Inc.
Neoplasms, Solid Tumors
A Trial Of SU14813 In Patients With Advanced Solid Malignancies
The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.
- Trial name
- NCT00982267
- Testing
- SU014813
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 77 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg
The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.
- Trial name
- MACS0375 (NCT00751036)
- Testing
- Nilotinib, Imatinib
- Where
- 32 sites in Argentina, Brazil and 7 more
- Volunteers
- 94 people
- Sponsor
- Novartis Pharmaceuticals
Infertility, ART
Automation of the In Vitro Fertilization Laboratory
Enrolled patients will undergo an Assisted Reproductive technology (ART) treatment using intracytoplasmic sperm injection (ICSI, the direct injection of a single sperm cell into an oocyte) as the method of insemination.
- Trial name
- NCT06581068
- Testing
- AURA assisted ART treatment
- Where
- 2 sites in Mexico
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Conceivable Life Sciences
COVID-19 Pneumonia, Cough
Kesuting Syrup in the Treatment of Corona Virus Disease 2019 (COVID-19)
This trial is an exploratory study, aiming to explore the preliminary efficacy and safety of Kesuting Syrup in the treatment of novel coronavirus pneumonia. It is planned to include a total of 200 cases.
- Trial name
- NCT05366231
- Testing
- Kesuting syrup, LianHuaQingWen Granules
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co Ltd